Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Genfit Says Safety/Tolerability Will Give Elafibranor An Edge In NASH

Dec 15 2016

• By Joseph Haas

Liver

Related Content

With Phase III NASH Endpoints In Place, Intercept May Reach Market By 2018

May 19 2015

Genfit Positions To Battle Intercept On Both NASH And PBC Fronts

Apr 08 2016

Endpoint Selection Could Help Determine The NASH Race

Nov 21 2016

Searching For Surrogate Endpoints Requires Teamwork

Sep 30 2013

'Clean Label' For Intercept's Ocaliva In PBC Bodes Well For NASH Claim

Jun 06 2016

Intercept rollercoaster continues with NASH, PBC updates

Nov 10 2014

Combination Strategies A Common Thread In NASH R&D

Nov 21 2016

Related Companies

Genfit SA

Intercept Pharmaceuticals, Inc.

Allergan plc

Allergan plc

Novartis AG

Takeda Pharmaceutical Co. Ltd.

Sanofi

Additional Topics

Commercial Drug Approval Standards Clinical Trials Business Strategies Research & Development Liver & Hepatic BioPharmaceutical

More from Business

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window